FALLBROOK – North County Parkinson's Support Group Fallbrook invites anyone interested to join their monthly support group meeting Friday, Oct. 27, 10 a.m. to noon at the Fallbrook Regional Health and Wellness Center, 1636 E. Mission Road.
The speakers will be Dr. Eugene P. Brandon, Chief Development Officer, BrainXell Therapeutics, and Dr. Anabel S. de la Garza Rodea, Director Medical Affairs, BrainXell Therapeutics. Their topic is “Parkinson's Cell Therapy & Upcoming Clinical Trial.”
Dr. Brandon, PhD, has over 30 years’ experience as an innovator of translational regenerative medicine, with particular expertise in neurobiology and cell and gene therapy product development. His pioneering and collaborative work includes development of the first pluripotent stem cell-derived islet replacement therapy for diabetes at CyThera/ViaCyte, and first-generation neurotrophic factor gene therapy for Parkinson’s and other neurodegenerative diseases (ALS, AD, HD) at Ceregene.
He is a trustee of the ALS Association, and recently served as Chair of the Research Committee.
Dr. de la Garza Rodea, MD, PhD, has 15+ years of experience in stem cell biology, tissue regeneration, surgery, and cell transplantation, with expertise in the musculoskeletal system, wound healing, angiogenesis, and soft tissues. She then joined the industry, working in translational research and clinical development for regenerative medicine at Genea Biocells and HepaTX, in skeletal muscle and liver systems, respectively.
In her subsequent position at Biosplice Therapeutics, she led and oversaw crucial preclinical studies of a compound in Phase 3 for osteoarthritis before shifting to the Medical Affairs department where she created, managed, and executed the strategic medical communication and publication plan and served on the scientific review committee.
BrainXell Therapeutics is a new private biotechnology company based in San Diego, translating the foundational research of Professor Suchun Zhang and cell production processes of BrainXell in Madison, Wisconsin, into autologous iPSC-based cell therapeutics for CNS disorders.
They have pre-clinical product candidates for Parkinson’s Disease and Spinal Cord Injury already in the pipeline, both supported by CIRM grants. Dr. Brandon and Dr. de la Garza believe that the personalized autologous approach will provide the best therapeutic solution for patients of all demographics in the long run and can be produced in an economically competitive fashion. BrainXell Therapeutics has recently completed construction of its own state-of-the-art GMP cell facility where the product candidates will be manufactured for upcoming clinical trials.
In addition to the speaker presentation, breakout groups held for a time of sharing, coffee and refreshments will follow the program.
This meeting is held in support of persons with Parkinson's disease, care partners and people interested in improving the world of those affected by Parkinson’s disease.
For more information, call Irene, 760-731-0171 or Lorie, 760-453-3045 or email [email protected].
Submitted by the Fallbrook Parkinson's Support Group.